Powered by

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)

Mar 26, 2018 - PR Newswire

 Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drug resistant bacterial infections, today announced positive top-line results from the Phase 2 study of its lead antibiotic candidate, an extended spectrum β-lactamase inhibitor known as AAI101.  The Phase 2 CACTUS study (Randomized, Double-Blind, Multi-Center Study ofCefepime/AAI101 in hospitalized adults withComplicatedUTIs) met all study objectives.  AAI101 was given ...